Critical role of activating transcription factor 4 in the anabolic actions of parathyroid hormone in bone by Yu, S et al.
Critical Role of Activating Transcription Factor 4 in the
Anabolic Actions of Parathyroid Hormone in Bone
Shibing Yu1, Renny T. Franceschi4,5, Min Luo1, Jie Fan2, Di Jiang4, Huiling Cao1, Tae-Geon Kwon7, Yumei
Lai3, Jian Zhang6, Kenneth Patrene1, Kurt Hankenson8, G. David Roodman1, Guozhi Xiao1*
1Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, 2Department of Surgery, University of Pittsburgh, Pittsburgh,
Pennsylvania, United States of America, 3Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of
America, 4Department of Periodontics and Oral Medicine, University of Michigan, Ann Arbor, Michigan, United States of America, 5Department of Biological Chemistry,
School of Dentistry, University of Michigan, Ann Arbor, Michigan, United States of America, 6Department of Medicine, School of Medicine, University of Michigan, Ann
Arbor, Michigan, United States of America, 7Department of Oral and Maxillofacial Surgery, School of Dentistry, Kyungpook National University, Daegu, Korea,
8Department of Animal Biology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
Abstract
Parathyroid hormone (PTH) is a potent anabolic agent for the treatment of osteoporosis. However, its mechanism of action
in osteoblast and bone is not well understood. In this study, we show that the anabolic actions of PTH in bone are severely
impaired in both growing and adult ovariectomized mice lacking bone-related activating transcription factor 4 (ATF4). Our
study demonstrates that ATF4 deficiency suppresses PTH-stimulated osteoblast proliferation and survival and abolishes
PTH-induced osteoblast differentiation, which, together, compromise the anabolic response. We further demonstrate that
the PTH-dependent increase in osteoblast differentiation is correlated with ATF4-dependent up-regulation of Osterix. This
regulation involves interactions of ATF4 with a specific enhancer sequence in the Osterix promoter. Furthermore, actions of
PTH on Osterix require this same element and are associated with increased binding of ATF4 to chromatin. Taken together
these experiments establish a fundamental role for ATF4 in the anabolic actions of PTH on the skeleton.
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Introduction
Parathyroid hormone (PTH) is a major regulator of calcium
homeostasis and has both catabolic and anabolic effects on
osteoblasts and bone that depend on the temporal pattern of
administration. Continuous administration of PTH decreases bone
mass whereas intermittent administration increases bone mass [1–
6]. The mechanism(s) responsible for these differing effects are
poorly understood. The anabolic activity of PTH has been
attributed to both direct actions of this hormone on osteopro-
genitor cells as well as indirect effects mediated by the production
of growth factors such as insulin-like growth factor-1 (IGF-1) and
basic fibroblast growth factor-2 (FGF-2) [7,8]. Most cellular
actions of PTH are mediated by the PTH-1 receptor, a G protein-
coupled receptor that is expressed in osteoblasts [9,10]. Binding of
PTH to its receptor activates multiple intracellular signaling
pathways that involve cAMP, inositol phosphates, intracellular
Ca2+, protein kinases A and C [11], and the extracellular signal-
related (ERK)/mitogen-activated protein kinase (MAPK) pathway
[12,13]. Activation of these signal transduction pathways ulti-
mately affects cellular behavior. In this regard, the anabolic actions
of PTH on bone have been attributed to increased proliferation of
osteopregenitors/osteoblasts [2,14,15] and/or decreased osteo-
blast apoptosis [6,16,17].
Although a number of transcription factors including cAMP
response element binding protein (CREB) [18,19], AP1 family
members [20–22], and Runx2 [20,23] have been implicated in the
molecular actions of PTH in osteoblasts, genetic studies have not
strongly linked any of these factors in the anabolic actions of this
hormone. To better understand the anabolic actions of PTH, it is
essential that the downstream signals induced by this hormone be
identified and evaluated for possible roles in bone formation. The
osteocalcin (Ocn) promoter has been an important tool for unraveling
the mechanisms mediating osteoblast-specific gene expression and
was used to identify a number of important transcription factors
and cofactors involved in Ocn gene expression [24–28]. Because
the Ocn gene is regulated by PTH [29,30], we have used it as a
model system for identifying new transcriptional mediators of
PTH action. We previously demonstrated that the OSE1
(osteoblast-specific element 1) in the proximal mOG2 promoter
[24] is necessary and sufficient for PTH induction of this gene
[31]. The OSE1 core sequence (TTACATCA) was subsequently
identified as a DNA binding site for the ATF4 transcription factor.
The critical role of ATF4 in osteoblast differentiation and bone
development was established using Atf4-deficient mice [26]. At the
cellular level, ATF4 is critical for proliferation and differentiation
as well as survival in osteoblasts [32,33]. We recently showed that
ATF4 is also required for PTH induction of Ocn expression in
osteoblasts [34]. Specifically, PTH elevated levels of ATF4 mRNA
and protein in a dose and time-dependent manner and increased
binding of ATF4 to OSE1 DNA. Furthermore, PTH stimulation
of Ocn expression was lost by siRNA downregulation of ATF4 in
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MC-4 cells and in primary bone marrow stromal cells from
Atf42/2 mice. Collectively, these studies demonstrate that ATF4 is
a novel downstream mediator of PTH signaling.
Osterix (Osx, or Sp7), a zinc-finger-containing transcription
factor of the sp family, is essential for osteoblast differentiation and
bone formation [35]. Since Osx is not detected in mice lacking
Runx2 [35], a master regulator of osteoblast differentiation
[25,36–38], it functions downstream of Runx2. However, the
molecular mechanisms whereby the Osx gene is transcriptionally
regulated are not well understood.
In the present study, we used ATF4-deficient mice to determine
whether ATF4 is more generally required for the in vivo anabolic
actions of PTH in bone as well as explore the mechanism used by
PTH to regulate ATF4 activity. As will be shown, loss of ATF4
greatly attenuated the anabolic effects of PTH. Furthermore,
ATF4 may participate in the PTH response by regulating the
expression of the Osterix transcription factor.
Results
The anabolic effects of PTH on bone are severely
impaired in growing Atf4-deficient mice
We first evaluated our hypothesis that ATF4 mediates the
anabolic actions of PTH in bone using a relatively simple ‘‘growing
mouse’’ model system, that has been widely used for studying the
anabolic actions of PTH, PTHrP, FGF2, and IGF-1 in bone [2–
4,8,39,40]. The advantages of this system are that it is less time
consuming and costly versus adult ovarectomized mouse models.
Furthermore, because young growing animals have relatively high
osteoblast activity, they are more sensitive to PTH than adults
[2,11,14,16–18,41–43]. Mice were treated with vehicle or PTH and
sacrificed 24 h after the last PTH injection. PTH-dependent
anabolic activity was evaluated in these mice using standard
biochemical and histomorphometric criteria. Atf42/2 mice grew
more slowly than wild type (wt) animals. The growth rate was
slightly but significantly increased by PTH treatment during d 6–18
in wt but not Atf42/2 animals (Fig. S1A). Atf42/2 femurs were also
shorter than wt or Atf4+/2 femurs. Consistent with results from a
previous study [3], PTH did not alter the length of femurs (Fig. S1B).
However, it did significantly increase the dry ash weight per femur in
wt and Atf4+/2 but not in Atf42/2 mice (Fig. S1C). Serum Pi and
calcium concentration (Fig. S1D and E) were not markedly affected
by PTH or ATF4 deficiency. Faxitron X-ray analysis of femurs
revealed that wt and Atf4+/2mice responded to PTH with markedly
increased radiopacity throughout the whole femur, with the most
dramatic increase in the metaphyseal region (Fig. S2, top and
middle). In contrast, PTH only slightly increased the radiopacity in
the same region of Atf42/2 femurs (Fig. S2, bottom). As shown in
Fig. 1, quantitative mCT analysis of femur histomorphometric
parameters showed that Atf42/2mice had a significant reduction in
bone volume/tissue volume (BV/TV), trabecular number (Tb.N),
and cortical thickness (Cort.Th) and a marked increase in trabecular
space (Tb.Sp) compared with the wt or Atf4+/2 littermates. These
data confirmed an essential role of ATF4 in bone that was previously
demonstrated by the Karsenty group [26]. As expected, in wt
femurs, intermittent PTH increased BV/TV, Tb.N, and Tb.Th by
5.4-fold, 2.7-fold, and 1.5-fold, respectively, and decreased Tb.Sp by
60 percent. Similar effects were also seen in Atf4+/2 mice (Fig. 1B).
In contrast, the PTH response was greatly attenuated in Atf42/2
mice where the following PTH responses were observed; BV/TV,
2.2-fold increase; Tb.N, 1.7-fold increase; Tb.Th, 1.1-fold increase;
Tb.Sp, 36 percent decrease. In all cases, the magnitude of PTH-
stimulated changes on BV/TV, Tb.N, Tb.Sp was dramatically
reduced in Atf42/2 mice relative to wt or Atf4+/2 mice (P,0.05,
PTH/veh-wt vs. PTH/veh-Atf42/2). Furthermore, PTH-stimulat-
ed increases in Cort.Th and Tb.Th were completely lost in Atf42/2
femurs. Because PTH similarly affected all trabecular and cortical
parameters in Atf4+/+ and Atf4+/2 mice, subsequent experiments
compared the PTH effects on bone only between wt and Atf42/2
mice.
We next measured effects of Atf4 gene ablation on PTH
stimulation of tibiae, vertebrae, and calvariae. The anabolic effect
of PTH on wt tibiae was so dramatic that the majority of the bone
marrow cavity was replaced by newly formed bone (Fig. 2A and
B). In Atf42/2 tibiae, while PTH still induced a small increase in
trabecular area, the magnitude of stimulation was significantly
reduced (5-fold in wt vs. 2.2-fold in Atf42/2)(P,0.05, PTH/veh-
wt vs. PTH/veh-Atf42/2)(Fig. 2C-E). Likewise, the PTH-stimu-
lated increase in the trabeculae of vertebrae (L5) was markedly
reduced in Atf42/2 mice (3-fold in wt vs. 2-fold in Atf42/2)
(P,0.05, PTH/veh-wt vs. PTH/veh-Atf42/2)(Fig. 2F–J). When
histological sections of calvariae were compared, PTH increased
the width of the calvariae by 1.8-fold in wt mice, a response that
was abolished in Atf42/2 animals (Fig. 2K–O).
Ablation of the Atf4 gene impairs PTH stimulation of
trabecular, but not cortical bone in 7-month-old
ovariectomized (OVX) mice
The experiments described above clearly establish a critical role
of ATF4 in the anabolic effects of PTH on long bones, vertebrae,
and calvariae in rapidly growing mice. However, it is possible that
results obtained from growing animals may be different from those
in adults due to possible effects of PTH and/or ATF4 on animal
growth or influences of animal growth on the anabolic response to
PTH, either of which could complicate the interpretation of the
results. In contrast, adult mice have a mature skeleton in which
these possible complications can be avoided. Furthermore, the
OVX mouse provides a model that may be more relevant to the
clinical applications of PTH in the treatment of osteoporosis. For
these reasons, we next evaluated whether ATF4 is required for the
anabolic response to PTH in 7-month-old OVX mice. OVX
surgery was successful as demonstrated by significant reduction in
BV/TV (65 percent), Tb.N (27 percent), and Tb.Th (18 percent)
and increased Tb.Sp (37 percent) relative to sham surgery (P,0.05,
wt-sham vs. wt-OVX) (Fig. S3). OVX surgery did not reduce
Cort.Th, which is consistent with results from rats [44], Interest-
ingly, OVX surgery did not significantly reduce bone parameters in
Atf42/2 animals (P.0.05, Atf42/2 -sham vs. Atf42/2 -OVX). As
shown in Fig. 3 A–C, similar to results from growing mice, ablation
of the Atf4 gene significantly decreased BV/TV and Tb.N and
increased Tb.Sp in adult OVX mice. In further agreement with
results in young mice, Atf42/2 animals exhibited a clearly
attenuated response to PTH. For example, while PTH increased
BV/TV by 7.8-fold in wt mice, this value was only increased 4.2-
fold in Atf42/2 animals. Similarly, while PTH still stimulated
formation of trabecular bone in Atf42/2trabeculae, the magnitude
of this response was significantly reduced compared to wt control
(P,0.05, PTH/veh-wt vs. PTH/veh- Atf42/2). In contrast to result
from growing mice, Cort.Th was not reduced by ablation of the Atf4
gene in adult OVX mice (0.2160.01 mm in wt vs. 0.1960.02 mm
in Atf42/2, P.0.05 wt vs. Atf42/2). Also, PTH was much less
effective in stimulating Cort.Th in adult OVX mice (24%) than in
growing mice (95%) (Figs. 1 and 3). Furthermore, no difference in
stimulation of cortical thickness by PTH was observed when wt and
Atf42/2 groups were compared (24% wt vs. 21% Atf42/2)(P.0.05,
PTH/veh-wt vs. PTH/veh-Atf42/2). As shown in Fig. 3D and E,
results from calcein double labeling of 7-month old OVX wt and
Atf42/2 tibia revealed that the PTH-stimulated increase in mineral
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apposition rate (MAR), an indicator of osteoblast function, was
significantly reduced by ATF4 deficiency (P,0.05, PTH/veh-wt vs.
PTH/veh-Atf42/2).
ATF4 deficiency significantly reduces basal and PTH-
stimulated proliferation in osteoblasts/preosteoblasts
PTH and PTHrP are both known to increase the proliferation
and numbers of osteoblasts [14,15,17,45]. ATF4 is also a positive
regulator of osteoblast proliferation and can be up-regulated by
PTH in these cells [33,34]. To determine whether ATF4 plays a role
in PTH regulation of osteoblast proliferation, sections of tibiae and
calvariae from wt and Atf42/2 mice treated with and without
intermittent PTH were analyzed for in vivo cell proliferation using a
Zymed BrdU immunostaining kit. As shown in Fig. 4A, B, and E, in
wt mice, PTH increased the percentage of proliferating osteoblasts/
preosteoblasts of tibial trabeculae by 2.8-fold relative to vehicle-
treated control. Ablation of the Atf4 gene resulted in a 50% decline
in basal proliferation. In addition, the PTH-stimulated increase in
proliferation was decreased by 40 percent (Fig. 4C–E). Similarly,
PTH-induced proliferation in calvarial periosteal osteoblasts was
also significantly reduced by ATF4 deficiency (Fig. 4F–J). As
expected, very few osteocytes were BrdU-positive in both tibiae and
calvariae. Note: basal proliferation rate of calvarial periosteal
osteoblasts was significantly higher than that of tibial trabecular
osteoblasts (28% vs. 4%). Therefore, ATF4 is critical for basal and
PTH-stimulated proliferation of osteoblasts/preosteoblasts in vivo.
PTH fails to reduce apoptotic death in Atf42/2
osteoblasts/osteocytes
Mature osteoblasts synthesize and deposit a mineralizing
extracellular matrix and become osteocytes. Both osteoblasts and
osteocytes can be lost through apoptosis. PTH signaling increases
Figure 1. PTH-stimulated bone was significantly reduced or lost in Atf42/2 femurs. A, two-dimensional (2D) reconstruction from mCT scan
of femurs from growing wt, Atf4+/2 and Atf42/2 mice treated with and without intermittent PTH for 28 d. B, quantitative analysis of bone volume/
tissue volume (BV/TV), trabecular number (Tb. N), trabecular thickness (Tb.Th), trabecular space (Tb.Sp), and cortical thickness (Cort. Th). *P,0.05 (veh
vs. PTH), { P,0.05 (wt-veh vs. Atf42/2-veh), #P,0.05 (PTH/veh-wt vs. PTH/veh-Atf42/2).
doi:10.1371/journal.pone.0007583.g001
ATF4 and PTH Anabolism
PLoS ONE | www.plosone.org 3 October 2009 | Volume 4 | Issue 10 | e7583
the survival of osteoblasts and osteocytes by reducing apoptosis
[6,16,17,45]. Our recent study shows that ATF4 is anti-apoptotic
in osteoblasts [33]. To determine whether ATF4 plays a role in
PTH-mediated anti-apoptosis, sections of tibiae were stained with
TUNEL and apoptotic cells were assessed. As shown in Fig. 4K
and L, ATF4 deficiency significantly increased the basal levels of
apoptosis. As expected, PTH dramatically reduced apoptotic
death of tibial trabecular osteoblasts/osteocytes by 48 percent,
which is consistent with results from previous studies [6,16,17,45].
Importantly, the PTH-stimulated decrease in apoptotic death was
completely abolished in Atf42/2 trabeculae (Fig. 4M–O). ATF4
was similarly required for PTH to inhibit apoptosis in cortical
osteocytes of tibiae (Fig. 4P). Collectively, ATF4 is essential for
PTH-mediated inhibition of apoptosis in osteoblasts/osteocytes in
vivo.
PTH-induced increase in expression of osteoblast
differentiation marker genes is dramatically reduced or
completely abolished in Atf42/2 animals
We next determined the effects of ATF4 deficiency on PTH
induction of osteoblast differentiation markers in vivo. Total RNA
was isolated from tibiae of wt and Atf42/2 mice treated with and
without PTH for 28 d and expression levels of osteoblast
differentiation marker genes were measured by quantitative real-
time PCR analysis. As shown in Fig. 5A, PTH dramatically
elevated the expression of genes known to be associated with
osteoblast differentiation including osteocalcin (Ocn) (2.2-fold), bone
sialoprotein (Bsp) (4.2-fold), alkaline phosphatase (Alp) (3.2-fold), a1(I)
collagen (Col1(I))(4.7-fold), osteopontin (Opn) (4.6-fold), and osterix (Osx)
(4.1-fold). Importantly, this PTH regulation was either dramati-
cally reduced or completely abolished in Atf42/2 tibiae. ATF4
deficiency also reduced basal Ocn and Osx mRNA levels.
Consistent with our previous report [34], PTH increased Atf4
mRNA 2.2-fold in wt tibiae, while Atf4 was undetectable in
Atf42/2 animals. In contrast, c-Fos and c-Jun, both early PTH-
induced genes, were not induced by PTH in either wt or Atf42/2
tibiae. As shown in Fig. 5B, the levels of IGF-1 and FGF-2 which
have both been implicated in the anabolic actions of PTH in bone
[7,8] were markedly reduced in plasma from Atf42/2 mice
compared to wt mice (P,0.05, wt vs. Atf42/2). However, their
levels were not significantly elevated by the treatment of
intermittent PTH in both wt or Atf42/2 animals (P.0.05, veh
vs. PTH).
Intermittent PTH increases in vivo Osx expression in
osteoblasts through a pathway requiring ATF4
Our above results demonstrate that ATF4 is essential for the
major anabolic actions of PTH on bone and is also required for
PTH-dependent induction of osteoblast differentiation. To begin
to address the mechanism underlying this response, we measured
the expression of Osterix (Osx) and Runx2 proteins, two critical
transcription factors that regulate osteoblast differentiation.
Initially, we used immunohistochemistry (IHC) to measure Osx
in the tibiae and calvariae of wt and Atf42/2 mice with or without
28 d anabolic PTH treatment. As shown in Fig. 6, in wt-vehicle-
treated tibiae, Osx-positive osteoblasts were only identified in the
trabeculae and cortical endosteum close to the growth plate
(Fig. 6A1, B1, and D1) and were almost undetectable in the same
Figure 2. PTH-stimulated bone is severely impaired in Atf42/2 tibiae, vertebrae, and calvariae. Representative H&E stained sections of
tibiae (A–E), vertebrae (L5) (F–J), and calvariae (K–O) are shown. Trabecular bone area versus total area of tibiae (E) and vertebrae (J) was measured
using an Image Pro Plus 6.2 software. The calvarial width was obtained from 20 random measurements throughout the whole calvaria using a SPOT
Advanced imaging software (O). *P,0.05 (veh vs. PTH), { P,0.05 (wt-veh vs. Atf42/2-veh), #P,0.05 (PTH/veh-wt vs. PTH/veh-Atf42/2).
doi:10.1371/journal.pone.0007583.g002
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regions close to the marrow (Fig. 6C1), indicating that cells in these
areas are still in the immature (preosteoblast) state. In contrast, in
the wt-PTH group, Osx-positive osteoblasts were identified on all
surfaces of trabeculae and endosteum throughout the tibia. PTH
increased the total number of Osx-positive cells per tibial section
by 3.2-fold in wt mice (Panel 2). ATF4 deficiency reduced the
numbers of Osx-positive cells by 50 percent (Panel 3). Strikingly,
although PTH slightly increased bone volume in Atf42/2 bone
(Fig. 1 and 2), it failed to elevate the numbers of Osx-positive cells
in Atf42/2 tibiae. Similar results were obtained in calvariae
(Fig. 6E). The IHC staining was highly specific since no signal was
detected in the non-immune IgG control group (Panel 5).
Consistent with IHC results, as shown in Fig. 6I, Western blot
analysis using protein extracts showed that PTH dramatically
elevated the level of Osx protein in wt tibiae. In contrast, Osx was
not detected by Western blot in extracts from Atf42/2 animals
(Fig. 6I). The level of Runx2 protein was slightly up-regulated by
PTH in the wt group, but not in Atf42/2 group. Unlike Osx, the
basal level of Runx2 was not reduced by ATF4 deficiency.
PTH1R protein, the major receptor for PTH and PTHrP
signaling in osteoblasts, was expressed in endosteal osteoblasts of
tibiae (Fig. 6F) and periosteal osteoblasts of calvariae and
hypertrophic chrodrocytes in the growth plate area (unpublished
data). The signal for PTH1R protein was weak in trabecular
osteoblasts that actively form new bone (unpublished data). In
contrast to results from a previous study showing that PTH1R is
down-regulated by PTH in cultured osteoblasts [46], PTH1R was
slightly increased by intermittent PTH treatment in vivo as
measured by IHC and Western blot analysis. Importantly, ATF4
deficiency did not reduce the level of PTH1R (Fig. 6F and I). In
addition, primary calvarial osteoblasts from wt and Atf42/2 mice
displayed an identical cAMP accumulation curve in response to
treatment of increasing concentrations of PTH in vitro. Taken
together, these results indicate that the impaired anabolic response
of skeleton to PTH observed in Atf42/2 animals cannot be
explained by a reduction in the level of PTH1R and/or cAMP
production. These results clearly demonstrate that: i) intermittent
PTH stimulates the expression of Osx and, to a lesser extent,
Figure 3. Effects of ATF4 deficiency on PTH stimulation in adult OVX bone. A, three-dimensional (3D) reconstruction from mCT scan of distal
femurs of adult OVX mice. B, sagittal view of 2D distal femur at 1.7–2.0 mm from the chondro-osseous junction. C, BV/TV, Tb. N, Tb.Th, Tb.Sp, and
Cort.Th. D, calcein double labeling of metaphyseal trabecular bone (magnification,x200). *P,0.05 (veh vs. PTH), { P,0.05 (wt-veh vs. Atf42/2-veh),
#P,0.05 (PTH/veh-wt vs. PTH/veh-Atf42/2).
doi:10.1371/journal.pone.0007583.g003
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Runx2, ii) PTH fails to stimulate Osx/Runx2 expression in the
absence of ATF4, and iii) ATF4 is also required for basal level Osx
expression.
Identification of a 132-bp ATF4-response element in
proximal Osx promoter
Osx is not detected in Runx22/2 mice [35], indicating that
Runx2 functions upstream of this factor and is essential for Osx
expression. However, the results described above showed that
ATF4 deficiency dramatically reduced the level of Osx protein
without decreasing Runx2, suggesting that Runx2 is not sufficient
for the maximal expression of Osx and that ATF4 has an
important role in Osx expression. To define the mechanism
whereby ATF4 regulates Osx, we examined the effect of ATF4
overexpression on Osx expression in MC-4 preosteoblast cells. As
shown in Fig. 7A, ATF4 dose-dependently increased levels of Osx
protein (top) and mRNA (bottom). We next examined whether
ATF4 up-regulates Osx by increasing gene transcription by using
a 21003/+68 mouse Osx promoter (Fig. 7 B). Using COS-7 cells,
which lack detectable Runx2, ATF4 had comparable activity to
Runx2 in terms of its ability to activate promoter activity (approx.
1.8-fold). Together, ATF4 and Runx2 maximally activated the Osx
promoter (3.2-fold induction). To further define the region of the
Osx promoter necessary for ATF4 responsiveness, several
constructs containing various deletion mutants of the mouse Osx
promoter were transiently transfected into COS-7 cells with and
without an ATF4 expression plasmid. Results showed that
luciferase activity of both control and ATF4-transfected groups
decreased with progressively larger 59 deletions. However, ATF4
stimulation was abrogated when a 132-bp region between bp
2215 to 283 was deleted (Fig. 7C). A putative ATF4-binding
sequence (CTTCCTCA) at 2201/2194 bp was identified in this
Figure 4. Effects of PTH on osteoblast proliferation and survival in wt and Atf42/2 bone. A–J, BrdU staining, sections of tibiae (A–D) and
calvariae (F–I) were stained using a Zymed BrdU immunostaining kit. Proliferating cells were stained brown (arrows) and non-proliferating cells were
stained blue. Proliferating cells on tibial trabecular surface or osteoid (E) or calvarial periosteal surface (J) were counted and normalized to total cells
from the same area. K–P, TUNEL staining, sections of tibiae were stained using the ApopTag Peroxidase In Situ Apoptosis Detection Kit. Apoptotic
osteoblasts and osteocytes (arrows) were stained brown and non-apoptotic cells were stained blue. Apoptotic osteoblasts and osteocytes in the
trabecular (O) and cortical bone (P) of tibiae were counted and normalized to total osteoblasts and osteocytes from the same area. *P,0.05 (veh vs.
PTH), { P,0.05 (wt-veh vs. Atf42/2-veh), #P,0.05 (PTH/veh-wt vs. PTH/veh-Atf42/2).
doi:10.1371/journal.pone.0007583.g004
ATF4 and PTH Anabolism
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region by using a TRANSFAC retrieval program. Introduction of
a 3-bp substitution mutation to this core sequence (from
CTTCCTCA to CTTgtaCA) completely abolished ATF4 activa-
tion (Fig. 7D). As shown in Fig. 7E, a DNA oligo probe from the
Osx promoter that contains the TTACATCA core sequence
bound to a factor(s) in nuclear extracts from COS-7 cells
transfected with an ATF4 expression vector. Importantly, this
binding (see arrow) was dramatically reduced by the addition of a
specific antibody against ATF4 but not by normal control IgG or
antibodies against cFos (an AP1 family member) or ATF2.
PTH stimulation of Osx gene transcription requires an
ATF4 response element
To study the mechanism whereby PTH regulates Osx, we next
evaluated the effect of PTH on mouse 21003/+68 Osx promoter
activity in MC-4 preosteoblast cells. As illustrated in Fig. 7F, PTH
stimulated promoter activity in a dose-dependent manner with a
detectable response seen at a PTH concentration of 10210 M
(significance at P,0.01). Measurable activation of the Osx
promoter was observed 0.5 h after PTH addition with maximal
induction occurring between 4–6 h (Fig. 7G). PTH-stimulated
Osx protein expression was entirely blocked by PKA inhibition
(Fig. 7H). The 132-bp ATF4-responsive element identified above
was also required for PTH induction of promoter (Fig. 7I).
Furthermore, the same 3-bp substitution mutation that abrogates
ATF4 activation dramatically reduced PTH-dependent activation
(Fig. 7J), indicating that this element is critical for the actions of
PTH on this promoter.
ATF4 is recruited to the endogenous Osx promoter in a
PTH-dependent manner
To determine whether ATF4 is associated with the endogenous
Osx promoter in vivo, we performed chromatin immunoprecipi-
tation (ChIP) assays using MC-4 cells with and without PTH
treatment. As shown in Fig. 7K and L, ATF4 specifically
interacted with a chromatin fragment of the proximal Osx
promoter that contains the ATF4-binding site identified above.
This interaction was not detected in primary calvarial osteoblasts
from Atf42/2 mice (data not shown). Furthermore, this interaction
was dramatically stimulated by PTH treatment. Supporting our
previous demonstration that the OSE1 site in the mOG2 promoter
mediates PTH induction of the gene [31,34], ATF4 also bound to
an ATF4-binding site (OSE1)-containing chromatin fragment of
the proximal mOG2 promoter in a PTH-dependent manner
(primers P3/P4). In contrast, ATF4 antibody failed to immuno-
precipitate a 39 chromatin fragment in the transcribed region of
the mOG2 gene that contains no ATF4-binding sites (primers
P5/P6).
Discussion
Our goals in this study were: 1) to determine whether the bone-
related transcription factor ATF4 plays a role in the anabolic
effects of PTH in bone, and 2) if so, to define the relevant
mechanisms. Our results clearly show that PTH-stimulated
increases in osteoblast proliferation, volume of long bones,
vertebrae, and calvariae as well as decreases in apoptosis are all
dramatically reduced or completely abolished in Atf4-deficient
mice. Equally importantly, PTH-induced bone in Atf42/2 mice
cannot mature due to a severe defect in osteoblast differentiation
as manifested by a defect in Osx expression. Therefore, this study
establishes a critical role for ATF4 in the anabolic actions of PTH
in bone.
In agreement with results from previous studies [14,47], we find
that intermittent PTH dramatically increases trabecular and
cortical bone volume. This PTH response is achieved at least in
part by stimulating the proliferation of osteoblasts and preosteo-
blasts and/or by inhibiting apoptotic death of osteoblasts and
osteocytes in vivo [2,6,45,47]. Effects of PTH on osteoblast
proliferation and survival can be reproduced in cultured
osteoblasts [15,16,48]. Importantly, this study demonstrates that
ATF4 plays a pivotal role in PTH stimulation of cell proliferation
in osteoblasts and preosteoblasts and attenuation of apoptosis in
osteoblasts and osteocytes in vivo. PTH can increase osteoblast
proliferation at least in part through ATF4-mediated expression of
cyclin D1 [33] because both factors are up-regulated by PTH in
osteoblasts [15,34]. The mechanism whereby ATF4 blocks
apoptosis in osteoblasts remains unknown. ATF4 deficiency also
increases apoptosis in lens fiber cells in a p53-dependent manner.
The embryonic lens in double homozygous p53/Atf42/2 mice
does not undergo apoptosis, which suggests possible involvement
of p53 in this process [49,50].
Accumulating evidence supports the concept that, in addition to
increasing osteoblast cell number, intermittent PTH also stimu-
lates osteoblast differentiation [4,51–53]. In agreement with these
results, the present study clearly demonstrates that: i) PTH
dramatically increases the in vivo expression of osteoblast
differentiation marker genes, including Ocn, Bsp, Alp, Opn, and
Col1(I); and ii) PTH strikingly elevates the numbers of Osx-positive
osteoblasts (i.e., mature or differentiating osteoblasts) and level of
Osx protein as demonstrated by both IHC and Western blot
analysis. Because PTH is able to stimulate the expression of many
osteoblast differentiation marker genes in cultured osteoblast-like
cells [12,30,31,54–57], it is likely that intermittent PTH also
activates these genes in vivo via a similar molecular mechanism.
Although part of the increased osteoblast activity in PTH-treated
animals is likely explained by a PTH-dependent increase in
Figure 5. Effects of PTH on expression of osteoblast marker
genes in wt and ATF4 deficient mice. A, quantitative real-time PCR,
total RNAs were isolated from tibiae and analyzed by quantitative real-
time RT-PCR using specific primers for Atf4, Ocn, Bsp, Col 1(I), ALP, Opn,
Pthrp, c-Fos, and c-Jun mRNAs, which were normalized to Gapdh mRNA.
*P,0.05 (veh vs. PTH), #P,0.05 (wt-veh vs. Atf42/2-veh). B, plasma
levels of IGF-1 and FGF-2 from mice using respective ELISA kits
according to the manufacturer’s instructions. *P,0.05 (veh vs. PTH),
{P,0.05 (wt-veh vs. Atf42/2-veh), #P,0.05 (PTH/veh-wt vs. PTH/
veh-Atf42/2).
doi:10.1371/journal.pone.0007583.g005
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Figure 6. PTH fails to promote osteoblast maturation/differentiation in the absence of ATF4. A–E, IHC analysis of Osx expression, sections
of tibiae (A–D) and calvariae (E) were immunohistochemically stained using a specific antibody against Osx protein. The nuclei of Osx-positive cells
(i.e., osteoblasts) were stained brown. The nuclei of preosteoblasts and other cells are stained blue. The total numbers of Osx-positive osteoblasts per
tibial (G) or calvarial (H) section were counted under microscope. F, sections of tibiae were stained using an antibody against PTH1R protein. I,
Western blot analysis, protein extracts were isolated from tibiae and analyzed for Osx, Runx2, and PTH1R proteins. *P,0.05 (veh vs. PTH), { P,0.05
(wt-veh vs. Atf42/2-veh), #P,0.05 (PTH/veh-wt vs. PTH/veh-Atf42/2). J, cAMP assay, primary calvarial osteoblasts from 3-d-old wt or Atf42/2 mice
were isolated, seeded at density of 56104 on 96-well plate, and treated with vehicle or increasing concentrations of human recombinant PTH(1-34)
for 5 min followed by measurement of cAMP.
doi:10.1371/journal.pone.0007583.g006
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Figure 7. PTH activates Osx gene transcription via an ATF4-responsive element in the proximal Osx promoter. A, MC-4 cells were
electroporated with indicated amount of ATF4 expression plasmid followed by Western blot. B, COS-7 cells were transfected with p1060mOsx-luc,
pRL-SV40, and indicated expression vectors followed by dual lucferase assays. C, COS-7 cells were transfected with various deletion constructs and
pRL-SV40 with and without ATF4 expression plasmid. D, COS-7 cells transfected with p215mOsx-luc or the same plasmid containing a 3-bp
substitution mutation in the putative ATF4-binding site and pRL-SV40 with and without ATF4 expression plasmid. E, EMSA, labeled wild-type DNA
probe was incubated with 2 mg nuclear extracts from COS-7 cells transfected with pCMV/ATF4 plasmid in the presence of normal control IgG (lane 3),
ATF4 antibody (lane 4), cFos antibody (lane 5), and ATF2 antibody (lane 6). Experiments were repeated 3–4 times and qualitatively identical results
were obtained. F and G, MC-4 cells transfected with p1003mOsx-luc and pRL-SV40 were treated with indicated concentration of PTH for 6 h (F) or
with 1027 M PTH for indicated times (G). H, MC-4 cells were treated with and without 1027 M PTH in the presence and absence of 10 mM of H89 for
6 h. I, MC-4 cells transfected as in Fig. 7C were treated with and without 1027 M PTH for 6 h. J, MC-4 cells transfected as in Fig. D were treated with
and without 1027 M PTH for 6 h. K, a schematic illustration of putative ATF4 binding sites in the 59 flanking regions of the Osx and osteocalcin gene
promoters and osteocalcin gene. L, ChIP assay of the Osx promoter in MC-4 cells treated with and without 1027 M PTH for 6 h. *P,0.05 (b-gal vs.
ATF4, Runx2, and ATF4 plus Runx2, or veh vs. PTH), #P,0.05 (ATF4 plus Runx2 vs. b-gal, ATF4, or Runx2).
doi:10.1371/journal.pone.0007583.g007
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osteoblast proliferation and/or reduction of apoptosis, our studies
suggest that PTH also increases osteoblast differentiation by
rapidly up-regulating Osx.
Importantly, experiments from the current study show that effects of
PTH on osteoblast differentiation are mediated by ATF4. Although
PTH increased osteoblast proliferation in Atf42/2 animals as
evidenced by significant increases in bone volume and nuclear BrdU
labeling (Figs. 1–3), expression of osteoblast marker genes and numbers
of Osx-positive osteoblasts were either dramatically reduced or
completely abolished in Atf42/2 animals. Furthermore, since the basal
levels of osteoblast differentiation markers are either slightly reduced or
not changed at all in Atf42/2 animals, the impaired differentiation
response to PTH cannot be explained by a nonspecific blockage in
osteoblast differentiation associated with ATF4 deficiency. Instead,
ATF4 appears to have a unique role in the PTH-dependent
component of osteoblast differentiation.
Further support for the concept that PTH actions are mediated
by ATF4 comes from mechanistic studies. Specifically, we showed
that PTH is a potent inducer of Osx expression in vivo and this
response is completely abolished by ATF4 deficiency. Further-
more, PTH directly activated Osx gene transcription in cultured
osteoblast-like cells, a response that required an ATF4 response
element located between 2201 and 2194 bp in the proximal
mouse Osx promoter. Introduction of a 3-bp substitution mutation
into this ATF4-binding site essentially eliminated the PTH
response. ChIP assays demonstrated that ATF4 binds to an
endogenous chromatin fragment near the putative ATF4-binding
site in the proximal Osx promoter in MC-4 cells. Of particular
significance, ATF4 binding to the Osx promoter is dramatically
enhanced by PTH. Collectively, these studies establish a unique
role for ATF4 in PTH-mediated induction of Osx and osteoblast
differentiation.
Runx2 is absolutely required for Osx expression, osteoblast
differentiation, and bone formation [35,58]. Nevertheless, ATF4
deficiency dramatically reduced the level of Osx protein without
altering Runx2, suggesting that Runx2 is not sufficient for
maximal Osx expression. ATF4 stimulated Osx gene transcription
in COS-7 cells that lack Runx2 protein to an extent similar to that
seen with Runx2. In addition, an ATF4 response element was
identified in the proximal region of the mouse Osx promoter.
These results demonstrate that both ATF4 and Runx2 are
essential for the maximal expression of Osx and are reminiscent of
our previous study showing cooperative interactions between these
two factors in regulating the Ocn gene [59].
It should be noted that ATF4 deficiency did not completely
block the anabolic actions of PTH since this hormone increased
bone volume in both growing and adult OVX bones from Atf42/2
mice (Figs. 1–3). This suggests that other factors must be involved
for the PTH response. c-Fos [3], cAMP response element binding
protein (CREB) [16], a major downstream target for PTH/cAMP
and calcium signals, cAMP-response element modulator
(CREM)[60], and Runx2 [16,23], a master regulator of osteoblast
differentiation and bone formation, have all been shown to
mediate components of the PTH anabolic response. Interestingly,
these factors are either structurally related to ATF4 (c-Fos and
CREM) or can interact with this factor (Runx2 and c-Fos) [59,61–
65]. Most recently, low-density lipoprotein-related protein 6
(LRP6)[66], a major component of the Wnt signaling pathway,
has been implicated in the anabolic actions of PTH in bone. It
would be interesting to determine whether ATF4 mediates the
PTH anabolic response via interactions with these factors or
signaling pathways.
PTH signaling may regulate ATF4 via several mechanisms.
First, PTH up-regulates Atf4 gene expression in cultured
osteoblasts as demonstrated by our recent study [34] as well as
in vivo (Fig. 5). Second, PTH post-translationally activates ATF4
via PKA [34], a major route for PTH signaling in osteoblasts.
PKA phosphorylation of ATF4 at its Ser254 residue mediates b-
adrenergic induction of Rankl mRNA expression in osteoblasts
[67]. ATF4 can also be directly phosphorylated and activated by
RSK2 [26], a growth factor-regulated serine-threonine protein
kinase activated by the Ras-Mitogen-Activated Protein Kinase
(MAPK) pathway. This phosphorylation is critical for ATF4
activity as well as bone formation [26]. Because PTH signaling
activates Erk/MAPK [48], an immediate upstream activator of
RSK2, ATF4 can be activated via the PTH-MAPK-RSK2
signaling pathway. Lastly, PTH promotes ATF4-Runx2 interac-
tions which are critical for osteoblast function and bone formation
[59,61,63]. This notion is supported by the fact that PTH up-
regulates both factors in osteoblasts [23,34].
Based on findings from this and other studies, we proposed a
working model for ATF4 to mediate PTH stimulation of osteoblast
function and bone formation (Fig. 8). Binding of PTH to its
receptor, PTH1R, activates PKA and probably other intracellular
signaling pathways, leading to up-regulation/activation of ATF4.
ATF4 subsequently increases proliferation of osteoblasts and/or
preosteoblasts via modulation of cyclin D1 protein, and attenuates
apoptotic death in osteoblasts and osteocytes, resulting in a
significant increase in the numbers of osteoblasts and/or
osteocytes. At the same time, ATF4 together with Runx2
maximally activates Osx expression and increases osteoblast
differentiation. The resulting increases in osteoblast number and
Figure 8. Proposed model for ATF4 mediation of PTH
stimulation of bone formation. Binding of PTH to PTH1R activates
PKA and leads to up-regulation of ATF4. ATF4 subsequently increases
proliferation and survival of osteoblasts. At the same time, ATF4
together with Runx2 maximally activates Osx expression and increases
osteoblast differentiation. These increases in osteoblast number and
differentiation lead to massive bone formation. Osx also negatively
regulates osteoblast proliferation, thus preventing excess bone
formation.
doi:10.1371/journal.pone.0007583.g008
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differentiation lead to bone formation. Osx also negatively
regulates osteoblast proliferation, thus preventing excess bone
formation [68].
Since ATF4 is known to regulate the expression of RANKL in
osteoblasts and thereby osteoclast differentiation [67,69], it will be
interesting to determine if ATF4 is also required for the catabolic
actions of PTH in bone.
In summary, this study establishes a critical role for ATF4 in the
anabolic actions of PTH in bone. ATF4 is necessary for PTH to
increase both osteoblast numbers and differentiation. Therefore,
ATF4 may provide a potential new therapeutic target for
improving bone mass and for treating metabolic bone diseases
such as osteoporosis.
Materials and Methods
Reagents
Tissue culture media and fetal bovine serum were obtained
from HyClone (Logan, UT). H89, DMSO, PTH1R antibody,
mouse monoclonal antibody against b-actin were purchased from
Sigma (St Louis, MO). Other reagents were obtained from the
following sources: antibodies against ATF4 (for Western blot),
Runx2, normal control IgGs and horseradish peroxidase-conju-
gated mouse or goat IgG from Santa Cruz (Santa Cruz, CA), and
Osterix antibody from Abcam Inc. (Cambridge, MA). ATF4
antibody used for EMSA was raised against epitope QETN-
KEPPQTVNPIGHLPESLIK (St Louis, MO). All other chemicals
were of analytical grade.
Atf4-deficient mice
Breeding pairs of Atf4 heterozygous mice were described
previously [34] and used to generate Atf4 wild-type (wt) (Atf4+/+),
heterozygous (Atf4+/2) and homozygous mutant (Atf42/2) mice for
this study. All research protocols were approved by the
Institutional Animal Care and Use Committee of the VA
Pittsburgh Healthcare System, where this study was conducted.
In vivo PTH administration
For the ‘‘growing mouse model’’, five-day-old mice were given
daily subcutaneous injections of vehicle (saline) or hPTH(1–34)
(60 ng/g body weight, Bachem, Torrance, CA) for 28 d. For the
‘‘adult OVX mouse model’’, four-month-old female mice were
anesthetized and ovariectomized as follows: A 1-cm midline
incision was made through the skin. The ‘‘white line’’ will be
visualized on the peritoneum and a second incision was made
along the white line through the peritoneum. Using long, straight
forceps, the left ovary was isolated and the connective tissue
between the ovary and kidney was dissected away. Straight forceps
with flat ends was used to pinch the uterine horn while another set
of straight forceps was used to tear the ovary away from the
uterine horn. The same was done on the right ovary. 6-0 PDS
(Polydioxanone Sutures, 6/0) was used to tie around the uterine
horn to provide hemostasis if necessary. 6-0 PDS was used to close
the innermost layer. Sterile surgical staples were used to close the
incision. Two months later mice were given daily subcutaneous
injections of vehicle or hPTH(1-34) (100 ng/g body weight) for
28 d. Mice were euthanized 24 h after last PTH injection. The
effects of these PTH dosing regimens on bone were determined by
both biochemical and histomorphometric criteria.
Gross evaluation and serum biochemistry
Body weight was recorded every another day. The length of the
femurs was measured using an electronic digital caliper. Faxitron
X-ray analysis of femurs was conducted at 27 kv and 7.5 seconds
(Faxitron X-Ray Corp., Wheeling, IL). Femurs were ashed at
800uC for 4 h and weighed. Serum calcium and Pi concentrations
were determined using kits from Pointe Scientific, Inc (Canton,
MI) following the manufacture’s instructions (Sigma Diagnostics).
Bone morphometric analyses by micro-computerized
tomography (mCT)
Upon termination of PTH or vehicle treatment, mice were
sacrificed and femurs were isolated. Fixed non-demineralized
femurs were used for mCT analysis at the Center for Bone Biology
using a VIVACT40 (SCANCO Medical AG) following the
standards of techniques and terminology recommended by
American Society for Bone and Mineral Research [70]. For
trabecular bone parameters, transverse CT slices were obtained in
the region of interest in the axial direction from the trabecular
bone 0.1 mm below the growth plate (bottom of the primary
spongiosa) to the mid-femur. Contours were defined and drawn
close to the cortical bone. The trabecular bone was then removed
and analyzed separately. 3D analysis was then performed on
trabecular bones slices. A 3-mm section was used to obtain mid-
femoral cortical bone thickness. The analysis of the specimens
involves the following bone measurements: bone volume fraction
(BV/TV, %), trabecular number (Tb. N), trabecular thickness (Tb.
Th), trabecular spacing (Tb. Sp), and cortical thickness (Cort.Th).
Histological evaluation
Tibiae, lumbar vertebrae (L5), and calvariae were fixed in PBS
buffered 10% formalin at 4uC for 24 h, decalcified in 10% EDTA
(pH 7.4) for 10–14 d, and embedded in paraffin. Longitudinal
sections of tibiae and vertebrae were cut at 4 mm and stained with
hematoxylin and eosin (H&E). Trabecular area of tibial sections
was measured in the proximal metaphysis beginning immediately
below the chondro-osseous junction to the mid-tibia. Calvariae
were bisected perpendicular to the sagittal suture through the
central portion of the parietal bones, parallel to lamboidal and
coronal sutures, and embedded in paraffin to obtain sections of a
standard area according to the method described by Zhao et al.
[71]. Trabecular area versus total bone area was measured using
an Image Pro Plus 6.2 software (Media Cybernetics, Inc, Bethesda,
MD). The calvarial width was the average value from 20 random
measurements of each calvaria (at least 6 samples per group) using
a SPOT Advanced imaging software (provided with the purchase
of the Olympus BX41 microscope).
Measurement of mineral apposition rate (MAR)
Mice were injected with calcein subcutaneously (20 mg/kg) at 6
and 2 d before sacrifice. Undecalcified tibia were fixed in 70%
ethanol, embedded in methylmethacrylate and sectioned at
10 mm. Calcein labeling was visualized using a Nikon E800
fluorescence microscope. The metaphyseal trabecular bone
projected into the marrow space was evaluated and the distance
between the all double-labeled areas was measured at a
magnification of 200x. MAR was calculated as mean distance
between the double labels divided by the number of the days
between the calcein injections. Histomorphometric analysis was
performed using BioQuant image analysis software (R&M Bio
Metrics, Nashville, TN, USA).
In vivo proliferation assay
Mice were injected intraperitoneally with 100 mg bromodeoxy-
uridine (BrdU)/12 mg fluorodeoxyuridine (FdU) per gram of body
weight 12 h before sacrifice. After sacrifice, sections of tibiae and
calvariae were obtained. To identify actively proliferating cells,
ATF4 and PTH Anabolism
PLoS ONE | www.plosone.org 11 October 2009 | Volume 4 | Issue 10 | e7583
nuclei that have incorporated BrdU were detected using a Zymed
BrdU immunostaining kit according to the manufacturer’s
instruction (Invitrogen, Carlsbad, CA). BrdU-positive cells (brown)
on the calvarial periosteal surface or in the osteoid of tibiae were
counted and normalized to the total numbers in the same area
[33]. BrdU-positive hematopoietic cells in marrow were not
counted.
In situ apoptosis detection
This assay is based on the classical TUNEL assay to examine
apoptosis by detecting DNA fragmentation. 4-mm sections of tibiae
were prepared and stained using the ApopTag Peroxidase In Situ
Apoptosis Detection Kit according to the manufacturer’s instruc-
tion (Millipore, Billerica, MA). Apoptotic osteoblasts and osteo-
cytes in tibiae were counted and normalized to the total cells from
the same area.
Immunohistochemistry (IHC)
Tibiae and calvariae were fixed, decalcified, and embedded in
paraffin. Sections of tibiae and calvariae were stained with
antibodies against Osx (Abcam Inc, Cambridge, MA) and PTH1R
(Sigma, St. Louis, MO) using the EnVision+System-HRP (DAB)
kit (Dako North America, Inc, Carpinteria, CA) according to the
manufacturer’s instructions. Briefly, slides were baked at 55uC for
45 min, deparaffinized in three washes of xylene, and rehydrated
in a decreasing ethanol gradient. Antigen retrieval was performed
using 0.1% trypsin for 10 min at 37uC in a humidified chamber.
Endogenous peroxidases were deactivated with 3% H2O2 in 1x
PBS for 10 min, and sections were blocked in blocking solution for
30 min at room temperature. Sections were incubated with
primary antibody (1:200 dilution for both osterix and PTH1R)
in blocking solution for 2 hours at 4uC. Sections were washed in
PBS three times and incubated with a donkey-anti-rabbit IgG-
HRP secondary antibody solution for 30 min at room tempera-
ture. After washing with PBS three times, HRP activity was
detected using a DAB substrate solution for 5 min at room
temperature. Sections were counter-stained with a Mayer’s
hematoxylin solution.
Measurement of plasma levels of IGF-1 and FGF-2 by
ELISA
Blood plasma samples were prepared from whole-blood samples
from mice of each group and plasma levels of IGF-1 and FGF-2
were measured by using ELISA kits (human FGF basic Quantikine
ELISA Kit, cat#: DFB50, and mouse IGF-I Quantikine ELISA
Kit, cat#: MG100, both from R&D Systems Inc, Minnepolis, MN
55413) according to the manufacturer’s instructions.
cAMP assay
Primary osteoblasts from calvariae of 3-d-old wt or Atf42/2
mice were isolated as described previously [72]. Cells were seeded
at a desity of 56104/well on 96-well plate and treated with vehicle
or increasing concentrations of human recombinant PTH(1-34)
for 5 min. Cells were then lysed with lysis reagent 1B and cell
lysates used for cAMP assay using a cAMP Biotrak Enzymeim-
munoassay (EIA) kit (cat #: RPN225, GE Healthcare Biosciences
Corp, Piscataway, NJ) according to the manufacturer’s instruc-
tions and the protein concentrations were measured using a BCA
protein assay kit (Pierce). cAMP was normalized to total protein.
Quantitative real-time RT/PCR and Western blot analysis
RNA isolation, reverse transcription (RT), regular PCR, and
quantitative real-time PCR analysis were performed as previously
described [34]. The DNA sequences of mouse primers used for
real-time PCR were summarized in Table 1. Western blot analysis
was performed as previously described [33]. RNAs or protein
extracts from at least six specimens in each group were used.
DNA constructs and site-directed mutagenesis,
transfection
pCMV/b-gal, pCMV/ATF4, and pCMV/Runx2 were previ-
ously described [62]. mOsx-luc containing different mouse Osx
promoter elements (21003/+68, 2567/+68, 2215/+68, and
283/+68) driving a firefly luciferase reporter gene were
constructed in the project laboratory by PCR subcloning promoter
fragments using mouse tail DNA as a template into pGL3-luc
vector (Promega, Madison, WI). Mutant p215mOsx-luc which
contains a 3-bp substitution mutation in a putative ATF4-binding
at positions 2198, 2197 and 2196 (from CTTCCTCA to
CTTgtaCA) was generated from the wild-type p215mOsx-luc by
PCR amplification using a QuickChangeTM XL Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA) using the following
primers: 59-GGT ACC CCT CCC TCT CTC GCC TTg taC
ATT GGA TCC GGA GTC TTC TCC GC-39 (forward); 59-
GCG GAG AAG ACT CCG GAT CCA ATG tac AAG GCG
AGA GAG GGA GGC GGT ACC-39 (reverse). Sequence
accuracy was confirmed by automatic DNA sequencing. For all
transfection experiments, the amount of plasmid DNAs (reporter
plasmid, 0.25 mg; normalization plasmid pRL-SV4, 10 ng; and
expression plasmid, 1.0 mg) was balanced as necessary with b-
galactosidase expression plasmid such that the total DNA was
constant in each group. Experiments were performed in triplicates
and repeated 3–4 times.
Nuclear extracts preparation and electrophoretic
mobility shift assay (EMSA)
Nuclear extracts were prepared from COS-7 cells transfected
with pCMV/ATF4 plasmids as previously described [73]. The
DNA sequences of the oligonucleotides used for EMSA were as
follows: GAT CCC TGC CTC CCT CTC TCG CCT TCC
TCA TTG GAT CCG GAG TCT TCG. DNA oligonucleotide
was labeled using a Biotin 39 end DNA Labeling Kit (cat #:
89818, Pierce Biotechnology Inc., Rockford, IL). Two mg of
nuclear extracts and 20 fmol biotin-labeled DNA probe were
incubated in 1x binding buffer for 30 min at room temperature.
Table 1. real-time PCR primers.
Gene
name 59 primer 39 primer
Alp TCCCACGTTTTCACATTCGG CCCGTTACCATATAGGATGGCC
Atf4 GAGCTTCCTGAACAGCGAAGTG TGGCCACCTCCAGATAGTCATC
Bsp AAGAGGAAGAAAATGAGAACGA GCTTCTTCTCCGTTGTCTCC
cFos AATGGTGAAGACCGTGTCAGGA CCCTTCGGATTCTCCGTTTCT
cJun GCCAACATGCTCAGGGAACAGGTG GCCCCTCAGCCCTGACAGTCTG
Col I(1) AGATTGAGAACATCCGCAGCC TCCAGTACTCTCCGCTCTTCCA
Gapdh CAGTGCCAGCCTCGTCCCGTAGA CTGCAAATGGCAGCCCTGGTGAC
Ocn TAGTGAACAGACTCCGGCGCTA TGTAGGCGGTCTTCAAGCCAT
Opn CCAATGAAAGCCATGACCACA CGTCAGATTCATCCGAGTCCAC
Osx AGAGGTTCACTCGCTCTGACGA TTGCTCAAGTGGTCGCTTCTG
Pth1r GATGCGGACGATGTCTTTACC GGCGGTCAAATACCTCC
doi:10.1371/journal.pone.0007583.t001
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For supershift assay, 1 mg of IgG or indicated antibodies were first
incubated with nuclear extracts prior to addition of DNA probe.
Protein–DNA complexes were separated on 4% polyacrylamide
gels in 1x TBE buffer, and transferred onto Biodyne B Nylon
Membrane (cat #: 77016, Pierce). The membrane was blocked in
1x blocking buffer, washed five times with 1x wash buffer, and
visualized by a Chemiluminescent Nucleic Acid detection Module
(cat #: 89880, Pierce, Rockford, IL).
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed using ATF4 antibody or control
IgG as described previously [62]. PCR primer pairs (Table 2) were
generated to detect DNA segments located near a putative ATF4-
binding site (CTTCCTCAT) at 2201/2193 (primers P1 and P2)
determined by the TRANSFAC retrieval program in the 59
flanking region of the Osx promoter, a previously identified ATF4-
binding site (OSE1) in osteocalcin gene 2 (mOG2) promoter (primers
3 and 4), and a mOG2 gene region (+177/+311) that contains no
ATF4-binding sites (primers P5 and P6) [62]. PCR products were
run on 3% agarose gel and stained with ethidium bromide.
Purified input chromatin was used to perform parallel PCRs with
the respective primer pairs.
Statistical analysis
Data was analyzed with a GraphPad Prism software (4.0). A
one-way ANOVA analysis was used followed by the Tukey test.
Students’ t test was used to test for differences between two groups
of data as needed. Data of Figs. 1, 2, 4, and 5 and S1-2 were from
growing mice and Figs. 3 and S3 from 7-month-old OVX mice.
For H&E, IHC, BrdU, and TUNEL studies, two to three sections
per specimen and at least six specimens in each group were used.
Results were expressed as means 6 standard deviation (SD).
Differences with a P,0.05 was considered as statistically
significant.
Supporting Information
Figure S1 Effects of PTH on animal growth, length and ash
weight of femurs, and serum Pi and calcium concentrations and
alkaline activity in wt and Atf42/2 mice. A, growth curve, B,
length of femur, C, dry ash weight of femur, D, serum Pi, E, serum
calcium. *P,0.05 (veh vs. PTH), { P,0.05 (wt-veh vs. Atf4-/--
veh).
Found at: doi:10.1371/journal.pone.0007583.s001 (1.78 MB
DOC)
Figure S2 Faxitron X-ray analysis of femurs from vehicle and
PTH-treated growing wt, Atf4+/2, and Atf4-/2 mice. Faxitron
X-ray analysis was conducted at 27 kv and 7.5 seconds.
Representative microradiographic images of femurs are shown.
Found at: doi:10.1371/journal.pone.0007583.s002 (1.45 MB TIF)
Figure S3 Effects of OVX surgery on bone parameters in wt
and Atf42/2 mice. Four-month-old female mice were first
ovariectomized. After two months, femurs were isolated for mCT
analysis. *P,0.05 (sham vs. OVX), { P,0.05 (sham(+/+) vs. sham
(2/2)).
Found at: doi:10.1371/journal.pone.0007583.s003 (0.16 MB
DOC)
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